Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007, 151(1):103-107 | DOI: 10.5507/bp.2007.019

Peripheral T-cell lymphoma, unspecified - the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry

Vit Prochazkaa, Marek Trnenyb, Robert Pytlikb, Ingrid Vasovab, Zdenek Kralb, David Beladab, Tomas Kozakb, Katerina Kubackovab, Hana Siffnerovab, Milan Matuskab, Milan Lysyb, Inge Bolomskab, Katarina Petrakovab, Barbora Otavovab, Jana Pribylovab, Jirina Svecovab, Tomas Papajika, Michaela Hamouzovab, Marketa Petrovab, Jana Zapletalovac, Katerina Langovac
a Department of Hemato-oncology, University Hospital, Olomouc, Czech Republic,
b Czech Lymphoma Study Group, Charles University General Hospital, Prague
c Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palackı University Olomouc

Background: Peripheral T-cell lymphoma, unspecified (PTCL-US) is one of the entities from the infrequent family of nodal mature T-cell lymphomas. The clinical course is aggressive, and despite multiagent chemotherapy, the median survival is about 2 years. Published data are limited to restrospective, mostly single-center studies or reviews and usually include more lymphoma subtypes.

Aim: To evaluate the current treatment modalities, clinical outcome and prognostic factors in unselected, new diagnosed patients with PTCL-US in the population of the central european region (Czech Republic).

Method: Czech Lymphoma Study Group is a national scientific organization which provides an on-line database registry which collects a data about almost all new diagnosed lymphoma patients since year 2000. All diagnostic biopsies were reviewed by a reference pathologist.

Results: We analyzed 63 patients with new diagnosis of PTCL-US. The median age was 59 years (25-81), chemotherapy (CHT) was administered in 56 of the 63 patients: anthracyclin-based CHT in 51 %, intensive CHT in 21 % and non-anthracyclin regimen was applied in 13 % of the patients. The overall response rate was 74.4 %, (CR in 57.4 %). After a median follow-up of 19.6 months, 41 % of the patients were in CR, 3.4 % in PR or stable disease and 55 % of the patients died. The estimated survival probability in 3 years was 36 %. Clinical stage (IV) and CR achievement were found to be independent survival predictors in a multivariate analysis.

Conclusions: Although the current treatment modalities are mostly ineffective in PTCL-US, appropriate intesive treatment may lead to prolonged remission but not survival.

Keywords: Peripheral T-cell lymphoma, PTCL, Chemotherapy, Survival, Prognosis

Received: October 6, 2006; Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prochazka, V., Trneny, M., Pytlik, R., Vasova, I., Kral, Z., Belada, D., ... Langova, K. (2007). Peripheral T-cell lymphoma, unspecified - the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. Biomedical papers, 151(1), 103-107. doi: 10.5507/bp.2007.019
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Nathwani BN, Ullrich F, Müller-Hermelink. Peripheral T-cel lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkins Lymphoma Classifi cation Project. Ann Oncol 2002; 13:140149. Go to original source... Go to PubMed...
    2. Lee MY, Tan TD, Feng AC, Liu MC. Clinicopathological analysis of malignant lymphoma in Taiwan, defi ned according to the World Health Organization classifi cation. Haematologica 2005; 90:17031705
    3. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD and Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 19922001. Blood 2006; 107(1):265276. Go to original source... Go to PubMed...
    4. Banks PM, Warnke RA. Mature T-cell and NK-cell neoplasms. In: Jaff e ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classifi cation of Tumours: Pathology and Genetics of Tumours of Hematopoetic and Lymphoid Tissues. Lyon, France: IARC Press, 2001. p. 189230.
    5. Savage KJ. Aggressive Peripheral T-Cell Lymphomas (Specifi ed and Unspecifi ed Types). In: American Society of Hematology Educational Book, USA: American Society of Hematology, 2005. p. 267277 Go to original source...
    6. Coiffi er B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with LNH84 regimen. J Clin Oncol 1990; 9:4550. Go to original source... Go to PubMed...
    7. Gisselbrecht C, Gaulard P, Lepage E, Coiffi er B, Briere J, Haioun C, Cazals-Hatem D, Bosly X, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J. Prognostic signifi cance of T-cell phenotype in aggressive non-Hodgkins lymphomas. Blood 1998; 92:7682.
    8. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffi er B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard P, Reyes F. Benefi t of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkins lymphoma: updated results of the prospective study LNH87-2. Groupe dEtude del Lymphomes de lAdulte. J Clin Oncol 1997; 15:11311137. Go to original source...
    9. Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A, Carreras E, Leon A, Arranz R, Fernandez de Sevilla A, Zuazu J, Garcia-Larana J, Rifon J, Varela R, Gandarillas M, SanMiguel J, Conde E. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GELTAMO experience. Ann Oncol 2003; 14:17681775. Go to original source... Go to PubMed...
    10. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S. Long-term follow-up of patients with peripheral T-cell lymphomas treated upfront with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20:15338. Go to original source... Go to PubMed...
    11. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccardo M, Benedetti F, Rambaldi A, Gianni A, Tarella C. Graft-versus-lymphoma eff ect in relapsed peripheral T-cell non-Hodgkins lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22:21722176. Go to original source... Go to PubMed...
    12. Tarella C, Caracciolo D, Ladetto M, Zallio F, Cuttica A, Ricca I, Gavarotti P, Bergui L, Corradini P, Pileri A. 11-yr follow-up of 184 non- Hodgkins lymphoma (NHL) patients treated with high-dose sequential (HDS) chemotherapy and autograft: highest response and best outcme in germinal-center derived subtypes [abstract]. 2000, Blood 96, 769a
    13. Mounier N, Gisselbrecht C, Briere J, Haioun C, Feugier P, Off ner F, Recher C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude del Lymphomes de l'Adulte. J Clin Oncol 2004; 22:28262834. Go to original source... Go to PubMed...
    14. Shipp M, Harrington D, Chairpersons et al. A predictive model for agressive non- Hodgkin's lymphoma: The International NHL Prognostic Factors Project. N Engl J Med 1993; 329:987994. Go to original source...
    15. Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005; 129:366372. Go to original source... Go to PubMed...
    16. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M. Peripheral T-cell lymphoma unspecifi ed (PTCL-U): a new prognostic model from a retrospective multicentric study. Blood 2004; 103:24742479. Go to original source... Go to PubMed...
    17. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, Bacci F, Falini B, Motta T, Paulli M, Artusi T, Piccioli M, Zinzani PL, Pileri SA. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic score. J Clin Oncol 2006; 24:24722479. Go to original source... Go to PubMed...
    18. Cheson BD, Horning SJ, Coiffi er B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an International Workshop to standardize Response Criteria for Non-Hodgkins Lymphomas. J Clin Oncol 1999; 17:12441253. Go to original source... Go to PubMed...
    19. Nie HH, Hadlai H, Jenkins JG, Steinbrenner K, Bent DH. (1979) SPSS (Statistical Package for the Social Sciences). New York, NY: McGraw-Hill
    20. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. JAMA 1958; 53:457481. Go to original source...
    21. Cox DR. Regression models and life-tabels. J Stat Soc 1982; 34:187220.
    22. Geissinger E, Bonzheim I, Krenacs L, Roth S, Reimer P, Wilhelm M, Müller-Hermelink H, Rüdiger T. Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations. J Pathol 2006; 210:172180. Go to original source... Go to PubMed...
    23. Ballester B, Ramuz O, Gisselbrecht C, Doucet G, Loi L, Loriod B, Bertucci F, Bouabdallah R, Devilard E, Carbuccia N, Mozziconacci MJ, Birnbaum D, Brousset P, Berger F, Salles G, Briere J, Houlgatte R, Gaulard P, Xerri L. Gene expresion profi ling identifi es molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2005; 14:156070 Go to original source...
    24. Asano N, Suzuki R, Kagami Y, Ishida F, Kitamura K, Fukutani H, Morishima Y, Takeuchi K, Nakamura S. Clinicopathologic and prognostic signifi cance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecifi ed. Am J Surg Pathol 2005; 29:12841292. Go to original source... Go to PubMed...
    25. Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, Dang NH. (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer 2005; 103:20918. Go to original source... Go to PubMed...
    26. Trneny M, Fekete S, Walewski J, Ladicka M, Kreuzbauer G, Skacel T. A retrospective study to assess relative dose intensities in patients with lymphoma in central european countries. In: Haematologica 2006;91(supplement 1), 11th Congress of the European Hematology Association, Amsterdam, Netherlands, 1518 June 2006. Go to original source...
    27. Ravandi F, Keating M. Alemtuzumab in T-cell malignances. In: Hillmen P, Witzig TE. Immunotherapy of lymphoid malignacies. Oxford: Atlas Medical Publishing; 2005. p. 189196.
    28. Dupuis J, Emile JF, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, Bouabdallah R, Berger F, Delmer A, Coiffi er B, Reyes F, Gaulard P. (2006) Prognostic signifi cance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecifi ed: a Groupe dEtude del Lymphomes de lAdulte (GELA) study. Blood prepublished paper, August 10 Go to original source...

    Return to the content